Anthracycline-dependent cardiotoxicity and extracellular matrix remodeling

Chest

Volumn 146, Issue 4, 2014, Pages 1123-1130

  Nikitovic, Dragana ^a   Juranek, Ivo ^b   Wilks, Martin F ^c   Tzardi, Maria ^a   Tsatsakis, Aristidis ^a   Tzanakakis, George N ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; REACTIVE OXYGEN METABOLITE; ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; COLORECTAL CANCER; DRUG CLASSIFICATION; DRUG SAFETY; EXTRACELLULAR MATRIX REMODELING; GENERAL PATHOLOGICAL PARAMETERS; HEART MUSCLE CELL; HUMAN; INFLAMMATORY INFILTRATE; LIPID PEROXIDATION; MEMBRANE DAMAGE; MYOCARDIAL DISEASE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; TUMOR MICROENVIRONMENT; EXTRACELLULAR MATRIX; HEART; HEART VENTRICLE REMODELING; PATHOLOGY; PHYSIOLOGY;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTOXICITY; EXTRACELLULAR MATRIX; HEART; HUMANS; VENTRICULAR REMODELING;

EID: 84907924789     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-0460     Document Type: Article

References (71)

1. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010; 102 ( 1 ): 14 - 25.
2. Brockmann H. Anthracyclinones and anthracyclines. (Rhodomycinone, pyrromycinone and their glycosides) [in German]. Fortschr Chem Org Naturst. 1963; 21 : 121 - 182.
3. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004; 56 ( 2 ): 185 - 229.
4. Germanakis I, Kalmanti M, Parthenakis F, et al. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol. 2006; 108 ( 2 ): 212 - 215.
5. Skovsgaard T, Nissen NI. Membrane transport of anthracyclines. Pharmacol Ther. 1982; 18 ( 3 ): 293 - 311.
6. Kiyomiya K, Matsuo S, Kurebe M. Mechanism of specifi c nuclear transport of adriamycin: The mode of nuclear translocation of adriamycin- proteasome complex. Cancer Res. 2001; 61 ( 6 ): 2467 - 2471.
7. Kumatori A, Tanaka K, Inamura N, et al. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci U S A. 1990; 87 ( 18 ): 7071 - 7075.
8. Amsterdam A, Pitzer F, Baumeister W. Changes in intracellular localization of proteasomes in immortalized ovarian granulosa cells during mitosis associated with a role in cell cycle control. Proc Natl Acad Sci U S A. 1993; 90 ( 1 ): 99 - 103.
9. Marco A, Arcamone F. DNA complexing antibiotics: daunomycin, adriamycin and their derivatives. Arzneimittelforschung. 1975; 25 ( 3 ): 368 - 374.
10. Bartkowiak J, Kapuscinski J, Melamed MR, Darzynkiewicz Z. Selective displacement of nuclear proteins by antitumor drugs having affi nity for nucleic acids. Proc Natl Acad Sci U S A. 1989; 86 ( 13 ): 5151 - 5154.
11. Rabbani A, Iskandar M, Ausio J. Daunomycin-induced unfolding and aggregation of chromatin. J Biol Chem. 1999; 274( 26): 18401- 18406.
12. Rabbani A, Davoodi J. Effects of anthracycline antibiotic, daunomycin on thymus chromatin: The role of chromosomal proteins. Gen Pharmacol. 1994; 25 ( 4 ): 787 - 793.
13. Mansilla S, Portugal J. Sp1 transcription factor as a target for anthracyclines: effects on gene transcription. Biochimie. 2008; 90 ( 7 ): 976 - 987.
14. Studzian K, Wasowska M, Piestrzeniewicz MK, et al. Inhibition of RNA synthesis in vitro and cell growth by anthracycline antibiotics. Neoplasma. 2001; 48 ( 5 ): 412 - 418.
15. Perego P, Corna E, De Cesare M, et al. Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem. 2001; 8 ( 1 ): 31 - 37.
16. Green PS, Leeuwenburgh C. Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta. 2002; 1588 ( 1 ): 94 - 101.
17. Zhu W, Zou Y, Aikawa R, et al. MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes. Circulation. 1999; 100 ( 20 ): 2100 - 2107.
18. Gille L, Nohl H. Analyses of the molecular mechanism of adriamycin- induced cardiotoxicity. Free Radic Biol Med. 1997; 23 ( 5 ): 775 - 782.
19. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998; 339 ( 13 ): 900 - 905.
20. Ky B, Vejpongsa P, Yeh ET, Force T, Moslehi JJ. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res. 2013; 113 ( 6 ): 754 - 764.
21. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004; 109 ( 25 ): 3122 - 3131.
22. Slordal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf. 2006; 29 ( 7 ): 567 - 586.
23. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977; 197 ( 4299 ): 165 - 167.
24. Outomuro D, Grana DR, Azzato F, Milei J. Adriamycin-induced myocardial toxicity: New solutions for an old problem? Int J Cardiol. 2007; 117 ( 1 ): 6 - 15.
25. Juranek I, Nikitovic D, Kouretas D, Hayes AW, Tsatsakis AM. Biological importance of reactive oxygen species in relation to difficulties of treating pathologies involving oxidative stress by exogenous antioxidants. Food Chem Toxicol. 2013; 61 : 240 - 247.
26. Nikitovic D, Corsini E, Kouretas D, Tsatsakis A, Tzanakakis G. ROS-major mediators of extracellular matrix remodeling during tumor progression. Food Chem Toxicol. 2013; 61 : 178 - 186.
27. Corsini E, Galbiati V, Nikitovic D, Tsatsakis AM. Role of oxidative stress in chemical allergens induced skin cells activation. Food Chem Toxicol. 2013; 61 : 74 - 81.
28. Dong F, Fang CX, Yang X, Zhang X, Lopez FL, Ren J. Cardiac overexpression of catalase rescues cardiac contractile dysfunction induced by insulin resistance: role of oxidative stress, protein carbonyl formation and insulin sensitivity. Diabetologia. 2006; 49 ( 6 ): 1421 - 1433.
29. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapyinduced cardiotoxicity: The role of troponins and other markers. Drug Saf. 2002; 25 ( 5 ): 301 - 311.
30. de Wolf, FA. Binding of doxorubicin to cardiolipin as compared to other anionic phospholipids-an evaluation of electrostatic effects. Biosci Rep. 1991; 11 ( 5 ): 275 - 284.
31. Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA. Time-dependent and tissue-specific accumulation of mt DNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation. 2003; 108 ( 19 ): 2423 - 2429.
32. Clementi ME, Giardina B, Di Stasio E, Mordente A, Misiti F. Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res. 2003; 23 ( 3B ): 2445 - 2450.
33. Maeda A, Honda M, Kuramochi T, Takabatake T. Doxorubicin cardiotoxicity: diastolic cardiac myocyte dysfunction as a result of impaired calcium handling in isolated cardiac myocytes. Jpn Circ J. 1998; 62 ( 7 ): 505 - 511.
34. Swift L, McHowat J, Sarvazyan N. Anthracycline-induced phospholipase A2 inhibition. Cardiovasc Toxicol. 2007; 7 ( 2 ): 86 - 91.
35. Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity. E xpert Opin Drug Saf. 2012; 11 ( suppl 1 ): S21 - S36.
36. Savaraj N, Allen LM, Sutton C, Troner M. Immunological modification of adriamycin cardiotoxicity. Res Commun Chem Pathol Pharmacol. 1980; 29 ( 3 ): 549 - 559.
37. Hasinoff BB, Patel D, Wu X. The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin. Cardiovasc Toxicol. 2013; 13 ( 1 ): 33 - 47.
38. Laurent GJ. Dynamic state of collagen: Pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol. 1987; 252 ( 1 Pt 1 ): C1 - C9.
39. Weber KT. Cardiac interstitium in health and disease: The fibrillar collagen network. J Am Coll Cardiol. 1989; 13 ( 7 ): 1637 - 1652.
40. Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC. Myofi broblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol. 2013; 10 ( 1 ): 15 - 26.
41. Robinson TF, Geraci MA, Sonnenblick EH, Factor SM. Coiled perimysial fi bers of papillary muscle in rat heart: Morphology, distribution, and changes in configuration. Circ Res. 1988; 63 ( 3 ): 577 - 592.
42. Rushmer RF, Thal N. The mechanics of ventricular contraction; a cinefluorographic study. Circulation. 1951; 4 ( 2 ): 219 - 228.
43. Chan KY, Xiang P, Zhou L, et al. Thrombopoietin protects against doxorubicin-induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks. Eur J Heart Fail. 2011; 13 ( 4 ): 366 - 376.
44. Kizaki K, Ito R, Okada M, et al. Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice. Pharmacol Res. 2006; 53 ( 4 ): 341 - 346.
45. Spallarossa P, Altieri P, Garibaldi S, et al. Matrix metalloproteinase- 2 and -9 are induced diff erently by doxorubicin in H9c2 cells: Th e role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res. 2006; 69 ( 3 ): 736 - 745.
46. Nikitovic D, Holmgren A. S-nitrosoglutathione is cleaved by the thioredoxin system with liberation of glutathione and redox regulating nitric oxide. J Biol Chem. 1996; 271 ( 32 ): 19180 - 19185.
47. Nikitovic D, Zacharis EA, Manios EG, et al. Plasma levels of nitrites/nitrates in patients with chronic atrial fi brillation are increased after electrical restoration of sinus rhythm. J Interv Card Electrophysiol. 2002; 7 ( 2 ): 171 - 176.
48. Mukhopadhyay P, Rajesh M, Batkai S, et al. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol. 2009; 296 ( 5 ): H1466 - H1483.
49. Goetzenich A, Hatam N, Zernecke A, et al. Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig. J Heart Lung Transplant. 2009; 28 ( 10 ): 1087 - 1093.
50. Dudnakova TV, Lakomkin VL, Tsyplenkova VG, Shekhonin BV, Shirinsky VP, Kapelko VI. Alterations in myocardial cytoskeletal and regulatory protein expression following a single Doxorubicin injection. J Cardiovasc Pharmacol. 2003; 41 ( 5 ): 788 - 794.
51. Shi J, Wu X, Surma M, et al. Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment. Cell Death Dis. 2013;4:e483.
52. Lin ST, Chou HC, Chen YW, Chan HL. Redox-proteomic analysis of doxorubicin-induced altered thiol activity in cardiomyocytes. Mol Biosyst. 2013; 9 ( 3 ): 447 - 456.
53. Kliment CR, Suliman HB, Tobolewski JM, et al. Extracellular superoxide dismutase regulates cardiac function and fibrosis. J Mol Cell Cardiol. 2009; 47 ( 5 ): 730 - 742.
54. Cleutjens JPM, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1995; 27 ( 6 ): 1281 - 1292.
55. Sun Y, Zhang JQ, Zhang J, Ramires FJA. Angiotensin II, transforming growth factor- b 1 and repair in the infarcted heart. J Mol Cell Cardiol. 1998; 30 ( 8 ): 1559 - 1569.
56. Horiguchi M, Ota M, Rifkin DB. Matrix control of transforming growth factor-b function. J Biochem. 2012; 152 ( 4 ): 321 - 329.
57. Sterba M, Popelova O, Lenco J, et al. Proteomic insights into chronic anthracycline cardiotoxicity. J Mol Cell Cardiol. 2011; 50 ( 5 ): 849 - 862.
58. Sopel M, Falkenham A, Oxner A, Ma I, Lee TD, Legare JF. Fibroblast progenitor cells are recruited into the myocardium prior to the development of myocardial fibrosis. Int J Exp Pathol. 2012; 93 ( 2 ): 115 - 124.
59. Fomovsky GM, Rouillard AD, Holmes JW. Regional mechanics determine collagen fiber structure in healing myocardial infarcts. J Mol Cell Cardiol. 2012; 52 ( 5 ): 1083 - 1090.
60. Ivanova M, Dovinova I, Okruhlicova L, et al. Chronic cardiotoxicity of doxorubicin involves activation of myocardial and circulating matrix metalloproteinases in rats. Acta Pharmacol Sin. 2012; 33 ( 4 ): 459 - 469.
61. Aupperle H, Garbade J, Schubert A, et al. Eff ects of autologous stem cells on immunohistochemical patterns and gene expression of metalloproteinases and their tissue inhibitors in doxorubicin cardiomyopathy in a rabbit model. Vet Pathol. 2007; 44 ( 4 ): 494 - 503.
62. Adamcova M, Potacova A, Popelova O, et al. Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits. Physiol Res. 2010; 59 ( 5 ): 831 - 836.
63. van Almen GC, Swinnen M, Carai P, et al. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol. 2011; 51 ( 3 ): 318 - 328.
64. Xie L, Terrand J, Xu B, Tsaprailis G, Boyer J, Chen QM. Cystatin C increases in cardiac injury: A role in extracellular matrix protein modulation. Cardiovasc Res. 2010; 87 ( 4 ): 628 - 635.
65. Zhao Y, McLaughlin D, Robinson E, et al. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. Cancer Res. 2010; 70 ( 22 ): 9287 - 9297.
66. Jirkovsky E, Popelova O, Krivakova-Stankova P, et al. Chronic anthracycline cardiotoxicity: Molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways. J Pharmacol Exp Th er. 2012; 343 ( 2 ): 468 - 478.
67. Burnell M, Levine MN, Chapman JA, et al. Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or highrisk node-negative breast cancer. J Clin Oncol. 2010; 28 ( 1 ): 77 - 82.
68. Lin J, Yu Y, Shigdar S, et al. Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer. PLoS ONE. 2012; 7 ( 11 ): e49277.
69. Venkatakrishnan CD, Tewari AK, Moldovan L, et al. Heat shock protects cardiac cells from doxorubicin-induced toxicity by activating p38 MAPK and phosphorylation of small heat shock protein 27. Am J Physiol Heart Circ Physiol. 2006; 291 ( 6 ): H2680 - H2691.
70. Arozal W, Watanabe K, Veeraveedu PT, et al. Effect of telmisartan in limiting the cardiotoxic effect of daunorubicin in rats. J Pharm Pharmacol. 2010; 62 ( 12 ): 1776 - 1783.
71. Gu R, Bai J, Ling L, et al. Increased expression of integrin-linked kinase improves cardiac function and decreases mortality in dilated cardiomyopathy model of rats. PLoS ONE. 2012; 7 ( 2 ): e31279.